ALK and lung cancer: Kirsten rat sarcoma (KRAS) mutations occur in about 30% of lung adenocarcinomas, and unlike other common oncogenic drivers (such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)), effective targeted therapeutic strategies for KRAS mutant lung cancer have been limited [16].